Back
ESC Premium Access

The thromboxane receptor antagonist NTP42 improves haemodynamics, inhibits remodelling, and restores function within the cardiopulmonary system in preclinical pulmonary arterial hypertension models

Session: Pulmonary circulation, pulmonary embolism, right heart failure e-posters
Topic: Pulmonary Hypertension
Speaker: Doctor E. Mulvaney (Dublin, IE)
Event: ESC Congress 2021 - The Digital Experience

Congress Presentation

0

About the speaker

Doctor Eamon Mulvaney

ATXA Therapeutics Limited, Dublin (Ireland)
0 follower

73 more presentations in this session

The novel noninvasive method for prediction of long-term specific therapy efficacy in patients with IPAH and inoperable CTEPH

Speaker: Mrs I. Lyapina (Kemerovo, RU)

Access
Abstract
Slides
1
Thumbnail

Early and long term prognostic accuracy of 4 acute pulmonary embolism mortality risk scores

Speaker: Doctor L. Oliveira (Ponta Delgada, PT)

Access
Abstract
Slides
0
Thumbnail

Novel genetic and molecular pathways in pulmonary arterial hypertension associated with connective tissue disease

Speaker: Doctor I. Hernandez Gonzalez (Valladolid, ES)

Access
Abstract
Slides
0
Thumbnail

Role of echocardiography to avoid misclassification of pulmonary hypertension associated with left heart disease as precapillary pulmonary hypertension.

Speaker: Assistant Professor J. Grignola Rial (Montevideo, UY)

Access
Abstract
Slides
1
Thumbnail

Survival of patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension listed for lung transplantation

Speaker: Doctor I. Magnani (Bologna, IT)

Access
Abstract
0
Thumbnail

Access the full session

Pulmonary circulation, pulmonary embolism, right heart failure e-posters

Speakers: Doctor E. Mulvaney, Mrs I. Lyapina, Doctor L. Oliveira, Doctor I. Hernandez Gonzalez, Assistant Professor J. Grignola Rial...
Access
0
Thumbnail

About the event

Image

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress
logo Image

Related content

ESC Premium Access

Endotrophin is significantly associated with disease severity and increased risk of adverse outcome in HFpEF but not in HFrEF patients

27 August 2021

ESC Premium Access

Urate lowering therapy is associated with a lower risk of heart failure hospitalisation or mortality in hyperuricaemic patients with heart failure: a comparative effectiveness study

27 August 2021

ESC Premium Access

Cardiovascular protection by combination of the selective nonsteroidal MR antagonist finerenone and the SGLT2 inhibitor empagliflozin in a preclinical model of hypertension-induced end-organ damage

27 August 2021

ESC 365 is supported by

logo Novo Nordisk